Finox Biotech Strengthens Leadership Team with 3 Senior Appointments(PresseBox) (Burgdorf, )
Luigi Marro has been appointed to the position of Chief Financial Officer (CFO) of Finox Biotech. Luigi is a seasoned financial professional who has worked in the pharmaceutical industry for more than 20 years. Luigi joined Serono (latterly Merck Serono) in Italy following graduation in 1991 and worked within financial and managerial roles at Serono and Merck Serono for almost 20 years - as Head of Worldwide Controlling for Manufacturing & Head of Business Performance and Strategy for Commercial Europe amongst other senior roles. Luigi then joined Voisins Consulting as Chief Operating Officer before joining Finox Biotech as CFO in May 2014. Luigi's experience in finance and the fertility market will be invaluable in helping Finox Biotech define and implement its financial strategy.
Ken Shields joins Finox Biotech as Executive Vice-President, Head of European Commercial Operations. Ken has a wealth of experience in sales and marketing roles in the area of women's health and devices. He worked as UK Business Unit Head of Fertility and Endocrinology at Merck Serono between 2003 and 2011 and latterly was the Managing Director of Women's Health at Gedeon Richter UK & Ireland. Ken will lead the European Commercial efforts as well as taking direct responsibility for the UK & Ireland business.
Nicole Stigemar has been appointed Executive Vice-President, Head of Marketing & Business Development. Nicole brings a deep knowledge of the fertility market and customers as well as an unrivalled understanding of the emerging markets to the company. Nicole will be responsible for driving the marketing analytics, strategy and execution providing value added activities and platform materials for the handpicked global sales teams. Her knowledge of emerging markets will be invaluable as Finox Biotech expands geographically over the coming years. Nicole's experience includes 7 years at Merck Serono in marketing & sales roles in Europe and Emerging markets before spending 2 years leading marketing for a group of IVF clinics. Latterly Nicole spent 5 years in senior marketing & commercial development roles at Amgen.
Gavin Jelic-Masterton, Chief Executive of FINOX Biotech commented, "the appointment to our Leadership team of these three senior professionals, with a combined experience of almost 40 years in the fertility market, underlines our commitment and belief to hiring the most experienced executives to ensure a rapid and high uptake of Bemfola® across Europe and the world. We are very excited to have Luigi, Ken and Nicole join Finox Biotech and are now fully ready to move to the next stage of our commercialisation plans".
bemfola® was produced using recombinant DNA technology. Both bemfola® and the reference product GONAL-f® are formulations of the naturally occurring hormone FSH, which plays a key role in human reproduction. bemfola® is the result of a targeted drug development process aimed to replicate as closely as possible the reference product. The brief to the development engineers when designing the bemfola® injector device was to produce a Pen that absolutely minimised the number of steps a patient needs to take when preparing the injection and to ensure that the patient and physician had maximum control and the least chance of a patient error. The result, the bemfola® Pen, is therefore a simple, single-use, once-a-day disposable device, which allows the patient to self-inject.
About bemfola® in other clinical development programs
Finox Biotech has agreed with the US-FDA to conduct a pivotal phase III study (FIN3002) for registration of bemfola® (AFOLIA) in the USA. A US-IND has been opened and the FIN3002 study is now in progress.